Confirmed graft flow following use of recombinant factor VIIa in coronary artery bypass grafting: a case report and literature review.

about

Confirmed graft flow following use of recombinant factor VIIa in coronary artery bypass grafting: a case report and literature review.

Item

http://www.wikidata.org/entity/Q36583813

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Confirmed graft flow following ...... report and literature review.

@ast

Confirmed graft flow following ...... report and literature review.

@en

type

Item

label

Confirmed graft flow following ...... report and literature review.

@ast

Confirmed graft flow following ...... report and literature review.

@en

prefLabel

Confirmed graft flow following ...... report and literature review.

@ast

Confirmed graft flow following ...... report and literature review.

@en

P1476

Confirmed graft flow following ...... report and literature review.

@en

P2093

Brian C Beldowicz

http://www.w3.org/2001/XMLSchema#string

C Scott Needham

http://www.w3.org/2001/XMLSchema#string

Jerome M McDonald

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac bypass haemostasis: putting blood through the mill.

Safety profile of recombinant factor VIIa.

Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis.

Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.

Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation.

Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.

P304

483-486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1540-8191.2006.00304.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16948764

http://www.w3.org/2001/XMLSchema#string